Skip to content

the effect of Daflon oral drug in the treatment of grade 1 and 2 hemorrhoids

Evaluation of the effect of Daflon oral drug compared to palliative drugs in the treatment of grade 1 and 2 hemorrhoids

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20250512065701N1
Enrollment
114
Registered
2025-09-14
Start date
2025-06-22
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemorrhoids. First degree hemorrhoids

Interventions

Intervention 1: The intervention group will receive a 500 mg Daflon tablet (Amin Pharmaceutical Company) every 12 hours and a 500 mg acetaminophen tablet daily for one month, along with painkillers (

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 18 years having grade 1 and 2 hemorrhoids willingness to participate in the study

Exclusion criteria

Exclusion criteria: patients who are candidates for immediate surgery cancer active inflammatory bowel disease a history of anal or rectal surgery severe or uncontrolled systemic disease pregnant or breastfeeding

Design outcomes

Primary

MeasureTime frame
Recovery time. Timepoint: before and 1 month after the intervention. Method of measurement: Time interval between intervention and recovery in days.;Wound size. Timepoint: before and 1 month after the intervention. Method of measurement: Hemorrhoid ulcer size according to Calibrated Probe.;Amount of bleeding. Timepoint: before and 1 month after the intervention. Method of measurement: Amount of blood lost during a month in cc by gravimetric method.;Need for surgery. Timepoint: One month after the intervention. Method of measurement: The need for surgery based on the decision of a specialist doctor.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMojtaba Shurmij

Tehran University of Medical Sciences

M.shurmij@gmail.com+98 21 6601 5493

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026